Pre-ePA (paper only; 428 OEs) | Post-ePA (ePA only; 528 OEs) | Post-ePA (ePA and paper; 597 OEs) | ||||||
---|---|---|---|---|---|---|---|---|
n | Percentage (95% CI) | n | Percentage (95% CI) | P valuea | n | Percentage (95% CI) | P valueb | |
Total MAEs | 18 | 4.2% (2.3–6.1) | 18 | 3.4 (1.9–5.0) | 0.64 | 24 | 4.0% (2.4–5.6) | 0.99 |
MAEs excluding omission due to unavailability of drug | 12 | 2.8% (1.2–4.4) | 11 | 2.1% (0.9–3.3) | 0.61 | 12 | 2.0% (0.9–3.1) | 0.54 |
Only MAEs due to unavailability of drug | 6 | 1.4% (0.2–2.5) | 7 | 1.3% (0.3–2.3) | 0.86 | 12 | 2.0% (0.9–3.1) | 0.62 |